Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28320583 | 0.97 | KDM4E (0.37) | KDM4ECA2PTGS1MMP12NFKB1 | |
| SCHEMBL11848454 | 0.83 | KDM4E (0.32) | KDM4ECA2PTGS1MMP12NFKB1 | |
| SCHEMBL11852174 | 0.81 | KDM4E (0.30) | KDM4ECA2PTGS1MMP12ALDH1A1 | |
| SCHEMBL29225994 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL11862232 | 0.77 | LMNA (0.39) | KDM4EALDH1A1LMNA | |
| SCHEMBL11322634 | 0.75 | — | — | |
| SCHEMBL11867991 | 0.75 | HDAC1 (0.37) | KDM4ELMNA | |
| SCHEMBL11852457 | 0.75 | HTT (0.40) | KDM4EALDH1A1 | |
| SCHEMBL11854369 | 0.75 | HDAC1 (0.37) | KDM4ELMNA | |
| SCHEMBL11858986 | 0.75 | HDAC1 (0.37) | KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302487-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2012-11-29 | — | — | US | claimed |
| EP-2494024-A1 | COMPOSITE | Revolymer Limited (GB) | 2012-09-05 | — | — | EP | claimed |
| WO-2011051681-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2011-05-05 | — | — | WO | claimed |
| US-20140171327-A1 | NOVEL COMPOSITE | REVOLYMER (U.K.) LIMITED (GB) | 2014-06-19 | — | — | US | disclosed |
| EP-2697355-A1 | PARTICLES WITH HYDROXYL VINYLIC COPOLYMER COATING SENSITIVE TO IONIC STRENGTH | Revolymer Limited (GB) | 2014-02-19 | — | — | EP | disclosed |
| US-20120302487-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| WO-2012140442-A1 | PARTICLES WITH HYDROXYL VINYLIC COPOLYMER COATING SENSITIVE TO IONIC STRENGTH | REVOLYMER LIMITED (GB) | 2012-10-18 | — | — | WO | disclosed |
| EP-2494024-A1 | COMPOSITE | Revolymer Limited (GB) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051681-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171327-A1 | NOVEL COMPOSITE | PUF60, C5, VCL | KDM4E 291/4885CA2 1432/4885PTGS1 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.